EU

Showing 15 posts of 252 posts found.

eu_and_fda

EU-US reach landmark deal on mutual recognition of manufacturing inspection

March 3, 2017
Medical Communications EMA, EU, FDA, US

The European Union and the US has announced that an agreement has been made to mutually recognise inspection of drug …

Myelofibrosis market to increase to be worth over $1 billion by 2025

November 16, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, US, myelofibrosis

The myelofibrosis market is expected to grow from $545.2 million in 2015 to $1.02 billion by 2025, almost doubling in …

Pfizer’s breast cancer drug gets EU approval

November 10, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMA, EU, Novartis, Pfizer, ibrance

Pfizer is celebrating the approval by the European Union of its breast cancer drug Ibrance, following a positive recommendation from …

microsoft_sign_on_german_campus

Adents and Microsoft pool resources to create new cloud platform

October 27, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Adents, EU, France, Microsoft

Adents, a French software developer for unique production identification and ‘Track & Trace’ solutions, and Microsoft have developed, with an …

ema_inside

EMA opens clinical trial data to public

October 25, 2016
Manufacturing and Production Amgen, AstraZeneca, EMA, EU, Kyprolis, clinical reports, clinical trials

The European Medicine Agency has begun to release to the public data on clinical trial via their own website. The …

cancer_drugs_-_credit_derek_k

€10.2 billion lost every year across the EU due to fake medicines

September 30, 2016
Manufacturing and Production, Medical Communications EU, European Union Intellectual Property Office, France, Germany, Italy, Spain, united kingdom

A report commissioned by the European Union Intellectual Property Office has shown that a staggering amount of money, €10.2 billion, …

bms

European Commission approves new RA treatment from BMS

September 6, 2016
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, EMA, EU, Orencia, RA, abatacept, approval, rheumatoid arthritis

Bristol-Myers Squibb has received approval from the European Commission for rheumatoid arthritis (RA) treatment Orencia (abatacept), making it the first …

gilead-sciences

Gilead gets EU approval for HIV-prevention treatment Truvada

August 23, 2016
Manufacturing and Production, Sales and Marketing EU, Gilead, HIV, PrEP, Truvada, prevention

Gilead Sciences has received marketing authorisation from the European Commission for once-daily Truvada (emtricitabine/tenofovir disoproxil), in combination with safer sex …

teva_copy

EU grants marketing authorisation for Teva’s asthma drug Cinqaero

August 19, 2016
Medical Communications, Sales and Marketing EU, Teva, approval, asthma, cinqaero, eosinophilic

The European Commission has granted marketing authorisation for Teva’s Cinqaero (reslizumab), as an odd-on therapy in adult patients with severe …

merck_incweb

MSD scores EU approval for Keytruda in lung cancer

August 3, 2016
Research and Development, Sales and Marketing EU, MSD, Merck, approval, keytruda, lung cancer

MSD, called Merck in the US and Canada, has announced that the European Commission has approved Keytruda (pembrolizumab) for patients …

allergan

IBS-D treatment Truberzi receives positive opinion from CHMP

July 26, 2016
Manufacturing and Production, Sales and Marketing Allergan, EU, Truberzi, diarrhoea. CHMP, irritable bowel syndrome

Global pharmaceutical company Allergan has announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of …

abbvie_0

AbbVie scores EU recommendation for shorter treatment of Viekirax in hepatitis C

July 25, 2016
Research and Development, Sales and Marketing EU, Gilead, Viekirax, hepatitis C

AbbVie has received an EU recommendation for a shorter treatment duration of Viekirax (ombitasvir/paritaprevir/ritonavir) plus ribavirin in genotype 4 chronic …

gilead-sciences

EU recommends PrEP in Gilead’s HIV prevention treatment

July 25, 2016
Research and Development, Sales and Marketing EU, Gilead, HIV, PrEP, prevention

Gilead has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines …

shire_image

Shire receives positive EU opinion for pancreatic cancer drug

July 25, 2016
Research and Development, Sales and Marketing CHMP, EU, Pancreatic cancer, Shire

Shire has announced that the EU regulator’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion …

opdivo_1

Opdivo to go before EU, US regulators in head and neck cancer

July 19, 2016
Manufacturing and Production, Research and Development EMA, EU, FDA, US, head and neck cancer, opdivo

Bristol-Myers Squibb has announced that its lead oncology drug, Opdivo (nivolumab), is set to go before regulators in the US …

The Gateway to Local Adoption Series

Latest content